Pembrolizumab-induced Myasthenia Gravis and Myocarditis

As the use of immune checkpoint inhibitors (ICPi) such as pembrolizumab is rapidly expanding in the fi eld of immuno-oncology, it is crucial for healthcare providers to be aware of their immune-related adverse events (irAE) which are thought to be driven by augmented immune response of T-cells. While neurologic irAE are underrepresented in literature, their consequences could lead to fatal outcomes. In this report, we describe the case of a patient with excellent performance status prior to pembrolizumab therapy who subsequently suffered myasthenic crisis eventually requiring tracheostomy and long-term mechanical ventilation.